Actinium Pharmaceuticals (ATNM) Sees Unusually-High Trading Volume

Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) shares saw unusually-high trading volume on Friday . Approximately 4,405,860 shares changed hands during trading, an increase of 277% from the previous session’s volume of 1,168,545 shares.The stock last traded at $0.32 and had previously closed at $0.30.

ATNM has been the topic of several recent research reports. Zacks Investment Research upgraded shares of Actinium Pharmaceuticals from a “hold” rating to a “buy” rating and set a $0.50 target price on the stock in a report on Monday, April 1st. Maxim Group restated a “buy” rating and set a $3.00 target price on shares of Actinium Pharmaceuticals in a report on Wednesday, March 20th. Finally, Oppenheimer set a $5.00 price target on shares of Actinium Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, February 26th. Five analysts have rated the stock with a buy rating, The company currently has a consensus rating of “Buy” and an average target price of $3.45.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last posted its quarterly earnings results on Tuesday, March 19th. The biotechnology company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06).

Several hedge funds and other institutional investors have recently bought and sold shares of ATNM. Vanguard Group Inc. boosted its stake in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc. now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the period. Vanguard Group Inc boosted its stake in Actinium Pharmaceuticals by 6.4% during the 3rd quarter. Vanguard Group Inc now owns 2,575,754 shares of the biotechnology company’s stock valued at $1,909,000 after purchasing an additional 154,403 shares during the period. PNC Financial Services Group Inc. boosted its stake in Actinium Pharmaceuticals by 23.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 1,031,210 shares of the biotechnology company’s stock valued at $399,000 after purchasing an additional 198,480 shares during the period. Oppenheimer & Co. Inc. boosted its stake in Actinium Pharmaceuticals by 69.3% during the 1st quarter. Oppenheimer & Co. Inc. now owns 175,512 shares of the biotechnology company’s stock valued at $84,000 after purchasing an additional 71,840 shares during the period. Finally, Renaissance Technologies LLC boosted its stake in Actinium Pharmaceuticals by 69.9% during the 1st quarter. Renaissance Technologies LLC now owns 139,347 shares of the biotechnology company’s stock valued at $67,000 after purchasing an additional 57,335 shares during the period.

COPYRIGHT VIOLATION WARNING: This news story was posted by Rockland Register and is the property of of Rockland Register. If you are accessing this news story on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The legal version of this news story can be accessed at https://rocklandregister.com/2019/05/31/actinium-pharmaceuticals-atnm-sees-unusually-high-trading-volume.html.

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)

Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.

Read More: What is diluted earnings per share (Diluted EPS)?

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.